Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor 4 (vIRF4) targets expression of cellular IRF4 and the myc gene to facilitate lytic replication

Journal of Virology

Volumn 88, Issue 4, 2014, Pages 2183-2194

  Lee, Hye Ra ^a   Doǧanay, Sultan ^b   Chung, Brian ^a   Toth, Zsolt ^a   Brulois, Kevin ^a   Lee, Stacy ^a   Kanketayeva, Zhansaya ^c   Feng, Pinghui ^a   Ha, Taekjip ^b   Jung, Jae U ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b University of Illinois at Urbana Champaign   (United States)

^c UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; DNA PRIMERS; GENE EXPRESSION REGULATION, VIRAL; HUMANS; IMMUNOBLOTTING; IN SITU HYBRIDIZATION, FLUORESCENCE; INTERFERON REGULATORY FACTORS; MICROARRAY ANALYSIS; PLASMIDS; PROTO-ONCOGENE PROTEINS C-MYC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 84893450331     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02106-13     Document Type: Article

References (44)

1. Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. 1995. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N. Engl. J. Med. 332:1186-1191. http://dx.doi.org/10.1056/NEJM199505043321802.
2. Dupin N, Diss TL, Kellam P, Tulliez M, Du MQ, Sicard D, Weiss RA, Isaacson PG, Boshoff C. 2000. HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood 95:1406-1412.
3. Sarid R, Flore O, Bohenzky RA, Chang Y, Moore PS. 1998. Transcription mapping of the Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) genome in a body cavity-based lymphoma cell line (BC-1). J. Virol. 72:1005-1012.
4. Bhatia K, Huppi K, Spangler G, Siwarski D, Iyer R, Magrath I. 1993. Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas. Nat. Genet. 5:56-61. http://dx.doi.org/10.1038/ng0993-56.
5. Dalla-Favera R, Bregni M, Erikson J, Patterson D, Gallo RC, Croce CM. 1982. Human c-myc oncogene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc. Natl. Acad. Sci. U.S.A. 79:7824-7827. http://dx.doi.org/10.1073/pnas.79.24.7824.
6. Rao PH, Houldsworth J, Dyomina K, Parsa NZ, Cigudosa JC, Louie DC, Popplewell L, Offit K, Jhanwar SC, Chaganti RS. 1998. Chromosomal and gene amplification in diffuse large B-cell lymphoma. Blood 92:234-240.
7. Yano T, Sander CA, Clark HM, Dolezal MV, Jaffe ES, Raffeld M. 1993. Clustered mutations in the second exon of the MYC gene in sporadic Burkitt's lymphoma. Oncogene 8:2741-2748.
8. Bubman D, Guasparri I, Cesarman E. 2007. Deregulation of c-Myc in primary effusion lymphoma by Kaposi's sarcoma herpesvirus latencyassociated nuclear antigen. Oncogene 26:4979-4986. http://dx.doi.org/10.1038/sj.onc.1210299.
9. Liu J, Martin HJ, Liao G, Hayward SD. 2007. The Kaposi's sarcomaassociated herpesvirus LANA protein stabilizes and activates c-Myc. J. Virol. 81:10451-10459. http://dx.doi.org/10.1128/JVI.00804-07.
10. Lubyova B, Kellum MJ, Frisancho JA, Pitha PM. 2007. Stimulation of c-Myc transcriptional activity by vIRF-3 of Kaposi sarcoma-associated herpesvirus. J. Biol. Chem. 282:31944-31953. http://dx.doi.org/10.1074/jbc.M706430200.
11. Nador RG, Cesarman E, Chadburn A, Dawson DB, Ansari MQ, Sald J, Knowles DM. 1996. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. Blood 88:645-656.
12. Acquaviva J, Chen X, Ren R. 2008. IRF-4 functions as a tumor suppressor in early B-cell development. Blood 112:3798-3806. http://dx.doi.org/10.1182/blood-2007-10-117838.
13. Shaffer AL, Emre NC, Lamy L, Ngo VN, Wright G, Xiao W, Powell J, Dave S, Yu X, Zhao H, Zeng Y, Chen B, Epstein J, Staudt LM. 2008. IRF4 addiction in multiple myeloma. Nature 454:226-231. http://dx.doi.org/10.1038/nature07064.
14. Aldinucci D, Celegato M, Borghese C, Colombatti A, Carbone A. 2011. IRF4 silencing inhibits Hodgkin lymphoma cell proliferation, survival and CCL5 secretion. Br. J. Haematol. 152:182-190. http://dx.doi.org/10.1111/j.1365-2141.2010.08497.x.
15. Xu D, Zhao L, Del Valle L, Miklossy J, Zhang L. 2008. Interferon regulatory factor 4 is involved in Epstein-Barr virus-mediated transformation of human B lymphocytes. J. Virol. 82:6251-6258. http://dx.doi.org/10.1128/JVI.00163-08.
16. Forero A, Moore PS, Sarkar SN. 2013. Role of IRF4 in IFN-stimulated gene induction and maintenance of Kaposi sarcoma-associated herpesvirus latency in primary effusion lymphoma cells. J. Immunol. 191:1476-1485. http://dx.doi.org/10.4049/jimmunol.1202514.
17. Lee HR, Brulois K, Wong L, Jung JU. 2012. Modulation of immune system by Kaposi's sarcoma-associated herpesvirus: lessons from viral evasion strategies. Front. Microbiol. 3:44. http://dx.doi.org/10.3389/fmicb.2012.00044.
18. Lee HR, Kim MH, Lee JS, Liang C, Jung JU. 2009. Viral interferon regulatory factors. J. Interferon Cytokine Res. 29:621-627. http://dx.doi.org/10.1089/jir.2009.0067.
19. Lee HR, Choi WC, Lee S, Hwang J, Hwang E, Guchhait K, Haas J, Toth Z, Jeon YH, Oh TK, Kim MH, Jung JU. 2011. Bilateral inhibition of HAUSPdeubiquitinase by a viral interferon regulatory factor protein. Nat. Struct. Mol. Biol. 18:1336-1344. http://dx.doi.org/10.1038/nsmb.2142.
20. Lee HR, Toth Z, Shin YC, Lee JS, Chang H, Gu W, Oh TK, Kim MH, Jung JU. 2009. Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor 4 targets MDM2 to deregulate the p53 tumor suppressor pathway. J. Virol. 83:6739-6747. http://dx.doi.org/10.1128/JVI.02353-08.
21. Heinzelmann K, Scholz BA, Nowak A, Fossum E, Kremmer E, Haas J, Frank R, Kempkes B. 2010. Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor 4 (vIRF4/K10) is a novel interaction partner of CSL/CBF1, the major downstream effector of Notch signaling. J. Virol. 84:12255-12264. http://dx.doi.org/10.1128/JVI.01484-10.
22. Kanno T, Sato Y, Sata T, Katano H. 2006. Expression of Kaposi's sarcoma-associated herpesvirus-encoded K10/10.1 protein in tissues and its interaction with poly(A)-binding protein. Virology 352:100-109. http://dx.doi.org/10.1016/j.virol.2006.04.009.
23. Xi X, Persson LM, O'Brien MW, Mohr I, Wilson AC. 2012. Cooperation between viral interferon regulatory factor 4 and RTA to activate a subset of Kaposi's sarcoma-associated herpesvirus lytic promoters. J. Virol. 86: 1021-1033. http://dx.doi.org/10.1128/JVI.00694-11.
24. Nakamura H, Lu M, Gwack Y, Souvlis J, Zeichner SL, Jung JU. 2003. Global changes in Kaposi's sarcoma-associated virus gene expression patterns following expression of a tetracycline-inducible Rta transactivator. J. Virol. 77:4205-4220. http://dx.doi.org/10.1128/JVI.77.7.4205-4220.2003.
25. Myoung J, Ganem D. 2011. Generation of a doxycycline-inducible KSHV producer cell line of endothelial origin: maintenance of tight latency with efficient reactivation upon induction. J. Virol. Methods 174:12-21. http://dx.doi.org/10.1016/j.jviromet.2011.03.012.
26. Toth Z, Maglinte DT, Lee SH, Lee HR, Wong LY, Brulois KF, Lee S, Buckley JD, Laird PW, Marquez VE, Jung JU. 2010. Epigenetic analysis ofKSHVlatent and lytic genomes. PLoS Pathog. 6:e1001013. http://dx.doi.org/10.1371/journal.ppat.1001013.
27. Brulois KF, Chang H, Lee AS, Ensser A, Wong LY, Toth Z, Lee SH, Lee HR, Myoung J, Ganem D, Oh TK, Kim JF, Gao SJ, Jung JU. 2012. Construction and manipulation of a new Kaposi's sarcoma-associated herpesvirus bacterial artificial chromosome clone. J. Virol. 86:9708-9720. http://dx.doi.org/10.1128/JVI.01019-12.
28. Raj A, van den Bogaard P, Rifkin SA, van Oudenaarden A, Tyagi S. 2008. Imaging individual mRNA molecules using multiple singly labeled probes. Nat. Methods 5:877-879. http://dx.doi.org/10.1038/nmeth.1253.
29. Gauzzi MC, Purificato C, Conti L, Adorini L, Belardelli F, Gessani S. 2005. IRF-4 expression in the human myeloid lineage: up-regulation during dendritic cell differentiation and inhibition by 1alpha,25-dihydroxyvitamin D3. J. Leukoc. Biol. 77:944-947. http://dx.doi.org/10.1189/jlb.0205090.
30. Hollis GF, Gazdar AF, Bertness V, Kirsch IR. 1988. Complex translocation disrupts c-myc regulation in a human plasma cell myeloma. Mol. Cell. Biol. 8:124-129.
31. Bemark M, Neuberger MS. 2000. The c-MYC allele that is translocated into the IgH locus undergoes constitutive hypermutation in a Burkitt's lymphoma line. Oncogene 19:3404-3410. http://dx.doi.org/10.1038/sj.onc.1203686.
32. Li X, Chen S, Feng J, Deng H, Sun R. 2010. Myc is required for the maintenance of Kaposi's sarcoma-associated herpesvirus latency. J. Virol.84:8945-8948. http://dx.doi.org/10.1128/JVI.00244-10.
33. Barrios C, Castresana JS, Ruiz J, Kreicbergs A. 1994. Amplification of the c-myc proto-oncogene in soft tissue sarcomas. Oncology 51:13-17.
34. Keller UB, Old JB, Dorsey FC, Nilsson JA, Nilsson L, MacLean KH, Chung L, Yang C, Spruck C, Boyd K, Reed SI, Cleveland JL. 2007. Myc targets Cks1 to provoke the suppression of p27Kip1, proliferation and lymphomagenesis. EMBO J. 26:2562-2574. http://dx.doi.org/10.1038/sj.emboj.7601691.
35. Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S, Palmiter RD, Brinster RL. 1985. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318:533-538. http://dx.doi.org/10.1038/318533a0.
36. Baresova P, Pitha PM, Lubyova B. 2012. Kaposi sarcoma-associated herpesvirus vIRF-3 protein binds to F-box of Skp2 protein and acts as a regulator of c-Myc protein function and stability. J. Biol. Chem. 287:16199-16208. http://dx.doi.org/10.1074/jbc.M111.335216.
37. Fujimuro M, Wu FY, ApRhys C, Kajumbula H, Young DB, Hayward GS, Hayward SD. 2003. A novel viral mechanism for dysregulation of beta-catenin in Kaposi's sarcoma-associated herpesvirus latency. Nat. Med. 9:300-306. http://dx.doi.org/10.1038/nm829.
38. Lehtonen A, Veckman V, Nikula T, Lahesmaa R, Kinnunen L, Matikainen S, Julkunen I. 2005. Differential expression of IFN regulatory factor 4 gene in human monocyte-derived dendritic cells and macrophages. J. Immunol. 175:6570-6579.
39. Grumont RJ, Gerondakis S. 2000. Rel induces interferon regulatory factor 4 (IRF-4) expression in lymphocytes: modulation of interferon-regulated gene expression by rel/nuclear factor kappaB. J. Exp. Med. 191:1281-1292. http://dx.doi.org/10.1084/jem.191.8.1281.
40. Gupta S, Jiang M, Anthony A, Pernis AB. 1999. Lineage-specific modulation of interleukin 4 signaling by interferon regulatory factor 4. J. Exp. Med. 190:1837-1848. http://dx.doi.org/10.1084/jem.190.12.1837.
41. Saito M, Gao J, Basso K, Kitagawa Y, Smith PM, Bhagat G, Pernis A, Pasqualucci L, Dalla-Favera R. 2007. A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma. Cancer Cell 12:280-292. http://dx.doi.org/10.1016/j.ccr.2007.08.011.
42. Shaffer AL, Wright G, Yang L, Powell J, Ngo V, Lamy L, Lam LT, Davis RE, Staudt LM. 2006. A library of gene expression signatures to illuminate normal and pathological lymphoid biology. Immunol. Rev. 210:67-85. http://dx.doi.org/10.1111/j.0105-2896.2006.00373.x.
43. Pathak S, Ma S, Trinh L, Eudy J, Wagner KU, Joshi SS, Lu R. 2011. IRF4 is a suppressor of c-Myc induced B cell leukemia. PLoS One 6:e22628. http://dx.doi.org/10.1371/journal.pone.0022628.
44. Hew K, Dahlroth SL, Venkatachalam R, Nasertorabi F, Lim BT, Cornvik T, Nordlund P. 2013. The crystal structure of the DNA-binding domain of vIRF-1 from the oncogenic KSHV reveals a conserved fold for DNA binding and reinforces its role as a transcription factor. Nucleic Acids Res. 41:4295-4306. http://dx.doi.org/10.1093/nar/gkt082.